Pharmaceutical MNCs Moving Full R&D Operations To China
This article was originally published in PharmAsia News
Johnson & Johnson recently inaugurated its Asia pharmaceutical R&D Center in Shanghai (PharmAsia News, April 17, 2009), putting China on par with its North American and European R&D bases. The firm attributes the move to not only cost considerations but also to China's huge disease pool and high-quality researchers. The 2004 to 2006 period saw pharmaceutical giants including Pfizer, GSK, Novartis and Sanofi-Aventis setting up their R&D centers in the country. With continuous development, MNCs are gradually moving from merely conducting clinical trials to completing their entire R&D process in the country. However, most life sciences innovations still come from Western countries and Japan as the lack of IP protection hampers China's bid to become a global hub for innovative pharma R&D. (Click here for more - Chinese language)
You may also be interested in...
SHANGHAI - Johnson & Johnson opened its Asia Pharmaceutical Research and Development Center in Shanghai April 16
In the current economy, e.l.f.’s value messaging is resonating with new consumers, contributing to an 8% jump in its fiscal 2021 first-quarter sales. The company expects continued volatility, but is optimistic about its robust digital game, growing skin-care clout and a newly announced partnership with Alicia Keys that it says will yield much more than “just another celebrity beauty line.”
Most of the major orthopaedics companies beat analyst expectations in the second quarter, but the ongoing COVID-19 pandemic raises uncertainties regarding procedure volumes for the rest of this year. See what Zimmer Biomet’s CEO Bryan Hanson said about it here.